A significant regulatory milestone for our digital long-term condition platform as we continue to make Aide as safe as possible for its users.
Over the past three years, Aide has been helping people across the UK in the NHS manage their asthma, type 2 diabetes and hypertension. This new medical device registration further cements Aide as a trusted and clinically validated digital platform that is now more capable than ever of supporting patients with long-term conditions.
Earlier this year, Aide demonstrated its potential with Suffolk Primary Care, where average medicine adherence rates for those using the intervention was 73.3%. Aide also identified that 50% of patients did not have an asthma action plan (AAP), which patients overuse their reliever inhaler (>2 times per week) and for what reason, and provided education on reliever and preventer inhaler use. AAP use is associated with a 70% reduction in mortality.
To learn more about the potential impact of Aide, read our study with Suffolk Primary Care.
